항체약물접합체(ADC) 시장 규모, 점유율, 성장 분석 : 제품별, 표적별, 기술별, 용도별, 지역별 - 업계 예측(2026-2033년)

Global Antibody Drug Conjugates (ADC) Market size was valued at USD 12.07 Billion in 2024 and is poised to grow from USD 13.13 Billion in 2025 to USD 25.78 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

The increasing incidence of cancer globally, coupled with a growing demand for innovative pharmaceuticals, is anticipated to significantly boost the sales of antibody drug conjugates (ADCs). The market is further propelled by heightened investments in biopharmaceutical research and technological advancements in ADC development. Expedited approval processes designed to accelerate market entry are expected to positively impact ADC sales as well. Additionally, the rising trend towards personalized medicine and its wider adoption will support market expansion. However, challenges such as high development costs, safety concerns related to toxicity, and competition from biosimilars pose notable constraints for companies operating in the antibody drug conjugate sector, potentially hindering overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (ADC) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates (ADC) Market Segments Analysis

The Antibody Drug Conjugates (ADC) Market is segmented based on the product, target, application, technology, and region. Based on the product, the Antibody Drug Conjugates (ADC) Market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others. Based on the application, the market is segmented into blood cancer,breast cancer, urothelial cancer & bladder cancer, and other cancer. Based on the target, the market is segmented into HER2, CD22, CD30, and others. On the basis of technology, the market is divided into cleavable linker, non-cleavable linker, linkerless, linker technology type, payload technology, and others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Driver of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is propelled by significant innovations in antibody engineering, linker chemistry, and cytotoxic payloads, which have resulted in the development of new and effective antibody drug conjugates. Enhanced conjugation techniques facilitate site-specific drug attachment, leading to improvements in stability and a reduction in immunogenicity. In addition, companies are investigating non-cleavable linkers, dual-drug ADCs, and bispecific antibodies as strategies to combat resistance. These advancements are crucial in expanding therapeutic windows, widening treatment indications, and minimizing adverse effects, ultimately transforming the landscape of antibody drug conjugate therapies.

Restraints in the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market faces several significant challenges that may hinder its growth. The production of ADCs necessitates complex design, development, and manufacturing processes, which require specialized facilities tailored for antibody generation, cytotoxic drug management, and conjugation procedures. This complexity results in substantial capital investments that can be a barrier to entry. Furthermore, the high costs associated with research and development due to rigorous preclinical and clinical testing phases are essential for ensuring safety and efficacy. These combined factors could limit the widespread adoption and overall expansion of antibody drug conjugates in the market.

Market Trends of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is witnessing a notable trend as companies expand their research and development efforts beyond oncology applications. While traditionally focused on cancer treatments, there is a growing interest in leveraging ADCs for various indications, particularly autoimmune disorders such as lupus and rheumatoid arthritis, by targeting specific immune cells for precise delivery of immunomodulatory agents. Furthermore, research is being directed towards combating bacterial infections through the targeting of pathogen-specific markers. This diversification of ADC applications is poised to enhance revenue generation and broaden the therapeutic impact of these innovative biopharmaceuticals across multiple disease areas.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Antibody Drug Conjugates (ADC) Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Global Antibody Drug Conjugates (ADC) Market Size by Target & CAGR (2026-2033)

• Market Overview
• HER2
• CD22
• CD30

Global Antibody Drug Conjugates (ADC) Market Size by Application & CAGR (2026-2033)

• Market Overview
• Blood Cancer
• Breast Cancer
• Urothelial Cancer
• Bladder Cancer
• Other Cancer

Global Antibody Drug Conjugates (ADC) Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Linker Technology
  • Cleavable Linker
  • Non-Cleavable Linker
  • Linkerless
• Payload Technology

Global Antibody Drug Conjugates (ADC) Market Size & CAGR (2026-2033)

• North America (Product, Target, Application, Technology)
  • US
  • Canada
• Europe (Product, Target, Application, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Target, Application, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Target, Application, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Target, Application, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Seagen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADC Therapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations